MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BioMarin Pharmaceutical Cash Conversion Cycle 2011-2026 | BMRN
Annual Cash Conversion Cycle BioMarin Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 733 | 819 | 769 | 679 | 653 | 561 | 527 | 458 | 539 | 356 | 295 | 290 | 335 | 324 | 604 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 819 | 290 | 529 |
Quarterly Cash Conversion Cycle BioMarin Pharmaceutical
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 883 | 841 | - | 662 | 897 | 908 | - | 808 | 754 | 692 | - | 367 | 328 | 680 | - | 733 | 586 | 616 | - | 423 | 746 | 640 | - | 715 | 890 | 702 | - | 694 | 697 | 632 | - | 801 | 846 | 830 | - | 709 | 693 | 737 | - | 748 | 652 | 680 | - | 592 | 572 | 664 | - | 487 | 587 | 594 | - | 466 | 486 | 677 | - | 564 | 645 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 908 | 328 | 673 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
AbbVie
ABBV
|
284 | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-25.8 K | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
72.3 | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
Amgen
AMGN
|
217 | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
235 | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Aurinia Pharmaceuticals
AUPH
|
612 | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
BioCryst Pharmaceuticals
BCRX
|
463 | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axon Enterprise
AXON
|
86.2 | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | Israel |